These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 21693461)

  • 21. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symmetric bis-benzimidazoles are potent anti-staphylococcal agents with dual inhibitory mechanisms against DNA gyrase.
    Dale AG; Hinds J; Mann J; Taylor PW; Neidle S
    Biochemistry; 2012 Jul; 51(29):5860-71. PubMed ID: 22746203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
    Durcik M; Lovison D; Skok Ž; Durante Cruz C; Tammela P; Tomašič T; Benedetto Tiz D; Draskovits G; Nyerges Á; Pál C; Ilaš J; Peterlin Mašič L; Kikelj D; Zidar N
    Eur J Med Chem; 2018 Jun; 154():117-132. PubMed ID: 29778894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV.
    Badshah SL; Ullah A
    Eur J Med Chem; 2018 May; 152():393-400. PubMed ID: 29751233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
    Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
    J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.
    Charrier C; Salisbury AM; Savage VJ; Duffy T; Moyo E; Chaffer-Malam N; Ooi N; Newman R; Cheung J; Metzger R; McGarry D; Pichowicz M; Sigerson R; Cooper IR; Nelson G; Butler HS; Craighead M; Ratcliffe AJ; Best SA; Stokes NR
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects.
    Ibrahim NM; Fahim SH; Hassan M; Farag AE; Georgey HH
    Eur J Med Chem; 2022 Jan; 228():114021. PubMed ID: 34871841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.
    Black MT; Stachyra T; Platel D; Girard AM; Claudon M; Bruneau JM; Miossec C
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3339-49. PubMed ID: 18625781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution of gyrase and topoisomerase IV on bacterial nucleoid: implications for nucleoid organization.
    Hsu YH; Chung MW; Li TK
    Nucleic Acids Res; 2006; 34(10):3128-38. PubMed ID: 16757578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study.
    Ibrahim TS; Almalki AJ; Moustafa AH; Allam RM; Abuo-Rahma GEA; El Subbagh HI; Mohamed MFA
    Bioorg Chem; 2021 Jun; 111():104885. PubMed ID: 33838559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
    Mitton-Fry MJ; Brickner SJ; Hamel JC; Brennan L; Casavant JM; Chen M; Chen T; Ding X; Driscoll J; Hardink J; Hoang T; Hua E; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Plotkin M; Reilly U; Robinson S; Schafer J; Shepard RM; Smith JF; Stone GG; Subramanyam C; Yoon K; Yuan W; Zaniewski RP; Zook C
    Bioorg Med Chem Lett; 2013 May; 23(10):2955-61. PubMed ID: 23566517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J; Robicsek A; Hooper DC
    Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus.
    Lahiri SD; Kutschke A; McCormack K; Alm RA
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5278-87. PubMed ID: 26077256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
    Takei M; Fukuda H; Kishii R; Hosaka M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3544-7. PubMed ID: 11709337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
    Stokes NR; Thomaides-Brears HB; Barker S; Bennett JM; Berry J; Collins I; Czaplewski LG; Gamble V; Lancett P; Logan A; Lunniss CJ; Peasley H; Pommier S; Price D; Smee C; Haydon DJ
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5977-86. PubMed ID: 24041906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
    Jakopin Ž; Ilaš J; Barančoková M; Brvar M; Tammela P; Sollner Dolenc M; Tomašič T; Kikelj D
    Eur J Med Chem; 2017 Apr; 130():171-184. PubMed ID: 28246042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
    Tiz DB; Skok Ž; Durcik M; Tomašič T; Mašič LP; Ilaš J; Zega A; Draskovits G; Révész T; Nyerges Á; Pál C; Cruz CD; Tammela P; Žigon D; Kikelj D; Zidar N
    Eur J Med Chem; 2019 Apr; 167():269-290. PubMed ID: 30776691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.
    Gruger T; Nitiss JL; Maxwell A; Zechiedrich EL; Heisig P; Seeber S; Pommier Y; Strumberg D
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4495-504. PubMed ID: 15561817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.